Capstone Therapeutics Corp
OTC:CAPS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Anhui Wantong Technology Co Ltd
SZSE:002331
|
CN |
|
N
|
Nelly Group AB (publ)
STO:NELLY
|
SE |
|
China Renaissance Holdings Ltd
HKEX:1911
|
CN |
|
Shenzhen Tongyi Industry Co Ltd
SZSE:300538
|
CN |
Capstone Therapeutics Corp
Operating Income
Capstone Therapeutics Corp
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Capstone Therapeutics Corp
OTC:CAPS
|
Operating Income
-$762k
|
CAGR 3-Years
22%
|
CAGR 5-Years
30%
|
CAGR 10-Years
26%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$20.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$11.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$16.2B
|
CAGR 3-Years
17%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$4.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$3.9B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
2%
|
CAGR 10-Years
12%
|
|
Capstone Therapeutics Corp
Glance View
Capstone Therapeutics Corp. is a biotechnology company. The company is headquartered in Tempe, Arizona. The firm is focused on development and commercialization of Apo E mimetic peptide AEM-28-14, through its investment in LipimetiX Development LLC. Apolipoprotein E is a 299 amino acid protein, which plays an important role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28-14, an analog of AEM-28, is a 28 amino acid mimetic of Apo E with an amino-hexanoic acid group and a phospholipid and both contain a domain, which anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors in the liver. AEM-28-14 as an Apo E mimetic, has the potential to enhance the clearance of triglyceride- and cholesterol-rich lipoproteins from the plasma.
See Also
What is Capstone Therapeutics Corp's Operating Income?
Operating Income
-762k
USD
Based on the financial report for Dec 31, 2019, Capstone Therapeutics Corp's Operating Income amounts to -762k USD.
What is Capstone Therapeutics Corp's Operating Income growth rate?
Operating Income CAGR 10Y
26%
Over the last year, the Operating Income growth was -38%. The average annual Operating Income growth rates for Capstone Therapeutics Corp have been 22% over the past three years , 30% over the past five years , and 26% over the past ten years .
